(Bold for FDA approved)
• Blocks mu opioid receptors, preventing exogenous opioids from binding there and thus preventing the pleasurable effects of opioid consumption
• Reduces alcohol consumption through modulation of opioid systems, thereby reducing the reinforcing effects of alcohol
• Can begin working within a few days but maximum effects may not be seen for a few weeks
• Nausea, vomiting, decreased appetite
• Dizziness, dysphoria, anxiety
• Injection site reactions (pain, tenderness, pruritis, induration, swelling, erythema, or bruising); in some cases injection site reactions may be very severe
• Eosinophilic pneumonia
• Hepatocellular injury (at excessive doses)
• Severe injection site reactions requiring surgery
unusual
not usual
• Wait
• Adjust dose
• If side effects persist, discontinue use
• Oral: 50 to 150 mg/day
• Injection: 380 mg every 4 weeks
• Tablet 25 mg, 50 mg, 100 mg
• Intramuscular formulation 380 mg/vial
• Has been studied in trials up to 1 year
• No
• Dose adjustment not generally necessary for mild impairment
• Not studied in moderate to severe renal impairment
• Has the potential to cause hepatocellular injury when given in excessive doses
• Dose adjustment not generally necessary for mild impairment
• Not studied in severe hepatic impairment
• Contraindicated in acute hepatitis or liver failure
• Limited available data
• Safety and efficacy have not been established
• Some patients may tolerate lower doses better
• Safety and efficacy have not been established
• Controlled studies have not been conducted in pregnant women
• Pregnant women needing to stop drinking may consider behavioral therapy before pharmacotherapy
• Not generally recommended for use during pregnancy, especially during first trimester
• Some drug is found in mother’s breast milk
• Recommended either to discontinue drug or bottle feed
Based on data Published online by Cambridge University Press
Compiled by Dr. Jash Ajmera